Assoc.-Prof. Dr. Kaan Boztug (MD) Our group works at the interface of inborn immune disorders and inherited predisposition to childhood tumors, aiming to understand fundamental mechanisms of immune surveillance relevant to pediatric oncology and immunotherapy approaches.
Dr. Martin Distel (PhD) Our research focus is on the generation of pediatric cancer models in zebrafish to better understand tumor initiation and tumor progression on a cellular and molecular level. In addition, zebrafish disease models are applied in small compound screens to identify therapeutic compounds.
Univ.-Prof. Dr. Oskar A. Haas (MD) Leukaemias are malignant diseases of the haematopoietic system that are caused by genetic defects. Our primary task is to diagnose and in detail characterise these diverse changes which are important for specific treatment and basic research, with the use of molecular and cytogenetic methods.
Dr. Florian Halbritter (PhD)
We combine "multi-omics" analysis with computational, statistical, and machine learning methods to dissect the molecular framework of pediatric cancers.
Univ.-Prof. Dr. Ruth Ladenstein (MD), MBA, cPM Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management.
Dr. Sabine Strehl, PhD Tracking down the faulty genes that cause leukamia with the ultimate goal to establish predictive biomarkers for the optimisation of risk-adapted therapy.